SLFN12 and thrombocytosis disease: Since anagrelide is used clinically to treat thrombocytosis and the drug causes the decline in the overall numbers of megakaryocytes (MKs) in a dose-dependent manner20, we speculated that anagrelide might induce MK cell number reduction through the PDE3A-SLFN12 apoptotic pathway.